PE20210045A1 - Anticuerpos agonistas contra pd-1 y usos de estos - Google Patents
Anticuerpos agonistas contra pd-1 y usos de estosInfo
- Publication number
- PE20210045A1 PE20210045A1 PE2020001188A PE2020001188A PE20210045A1 PE 20210045 A1 PE20210045 A1 PE 20210045A1 PE 2020001188 A PE2020001188 A PE 2020001188A PE 2020001188 A PE2020001188 A PE 2020001188A PE 20210045 A1 PE20210045 A1 PE 20210045A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- whose amino
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 102000048362 human PDCD1 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a un anticuerpo que se fija a la PD-1 humana, que comprende: 1) una region variable de la cadena pesada (HCVR) cuya secuencia de aminoacidos es la SEQ ID NO:3; y 2) una region variable de la cadena liviana (LCVR) cuya secuencia de aminoacidos es la SEQ ID NO:4 , en donde la HCVR comprende una HCDR1, HCDR2 y HCDR3, y la LCVR comprende una LCDR1, LCDR2, y LCDR3, en donde la secuencia de aminoacidos de la HCDR1 es la SEQ ID NO: 5, HCDR2 es la SEQ ID NO: 6 y HCDR3 es la SEQ ID NO: 7, la secuencia de aminoacidos de la LCDR1 es la SEQ ID NO: 8, LCDR2 es la SEQ ID NO: 9 y LCDR3 es la SEQ ID NO: 10, y en donde el anticuerpo es una IgG1. Comprende ademas una HC cuya secuencia de aminoacidos es la SEQ ID NO:1 y una LC cuya secuencia de aminoacidos es la SEQ ID NO:2. Tambien se refiere a una composicion farmaceutica que comprende dicho anticuerpo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637643P | 2018-03-02 | 2018-03-02 | |
| PCT/US2019/019076 WO2019168745A1 (en) | 2018-03-02 | 2019-02-22 | Pd-1 agonist antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210045A1 true PE20210045A1 (es) | 2021-01-08 |
Family
ID=65686121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001188A PE20210045A1 (es) | 2018-03-02 | 2019-02-22 | Anticuerpos agonistas contra pd-1 y usos de estos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10493148B2 (es) |
| EP (1) | EP3759139A1 (es) |
| JP (3) | JP7071521B2 (es) |
| KR (2) | KR102536014B1 (es) |
| CN (4) | CN118903407A (es) |
| AR (1) | AR114127A1 (es) |
| AU (2) | AU2019228474B2 (es) |
| BR (1) | BR112020015983A2 (es) |
| CA (1) | CA3092064C (es) |
| CL (1) | CL2020002180A1 (es) |
| CO (1) | CO2020010188A2 (es) |
| CR (1) | CR20200375A (es) |
| DO (1) | DOP2020000153A (es) |
| EA (1) | EA202091809A1 (es) |
| EC (1) | ECSP20053544A (es) |
| IL (1) | IL276340A (es) |
| JO (1) | JOP20200210A1 (es) |
| MA (1) | MA52414A (es) |
| MX (1) | MX2020009124A (es) |
| PE (1) | PE20210045A1 (es) |
| PH (1) | PH12020551463A1 (es) |
| SA (1) | SA520420082B1 (es) |
| SG (1) | SG11202008437WA (es) |
| TW (1) | TWI708787B (es) |
| WO (1) | WO2019168745A1 (es) |
| ZA (1) | ZA202004601B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11207393B2 (en) * | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| MX2019014577A (es) | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y metodos de uso. |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN112236454B (zh) * | 2018-03-20 | 2022-09-13 | 上海药明生物技术有限公司 | 新型抗pd-1抗体 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| SG11202112506SA (en) | 2019-05-10 | 2021-12-30 | Univ California | Modified pluripotent cells |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| EP4107189A4 (en) * | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| IL297029A (en) * | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Multimeric binding compounds as pd-1 agonists |
| US20230183347A1 (en) * | 2020-05-25 | 2023-06-15 | Foundation For Biomedical Research And Innovation At Kobe | PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease |
| LT4157876T (lt) | 2020-05-26 | 2024-10-25 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antikūnai |
| US20240317859A1 (en) * | 2021-05-13 | 2024-09-26 | Foundation For Biomedical Research And Innovation At Kobe | Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases |
| JP2024539457A (ja) | 2021-11-19 | 2024-10-28 | ミロバイオ・リミテッド | 操作されたｐｄ－１抗体及びその使用 |
| WO2023147470A2 (en) * | 2022-01-28 | 2023-08-03 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
| CN119183385A (zh) * | 2022-04-13 | 2024-12-24 | 加利福尼亚大学董事会 | 免疫检查点接合子对免疫细胞的抑制 |
| CA3260209A1 (en) * | 2022-07-06 | 2024-01-11 | Santa Ana Bio Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE, ALLERGIC AND INFLAMMATORY DISEASES |
| TW202423966A (zh) * | 2022-08-19 | 2024-06-16 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及以pd-1促效劑抗體治療自體免疫疾病之方法 |
| WO2024050421A2 (en) * | 2022-08-30 | 2024-03-07 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting programmed cell death protein 1 (pd-1) |
| EP4608515A1 (en) | 2022-10-25 | 2025-09-03 | Seismic Therapeutic, Inc. | Variant igg fc polypeptides and uses thereof |
| CN116284447A (zh) * | 2023-02-20 | 2023-06-23 | 苏州大学 | 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用 |
| WO2024196694A2 (en) * | 2023-03-17 | 2024-09-26 | Eli Lilly And Company | Pd-1 agonist antibodies and methods of treating inflammatory or autoimmune skin diseases with a pd-1 agonist antibody |
| WO2025042732A1 (en) * | 2023-08-18 | 2025-02-27 | Eli Lilly And Company | Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody |
| CN120424213A (zh) * | 2024-02-02 | 2025-08-05 | 英诺湖医药(杭州)有限公司 | 特异性结合pd-1的单克隆抗体及其医药用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| US20120269806A1 (en) | 2007-08-21 | 2012-10-25 | The General Hospital Corporation | Methods of inducing tolerance |
| EP2342228B1 (en) * | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| WO2011100841A1 (en) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| WO2013022091A1 (ja) * | 2011-08-11 | 2013-02-14 | 小野薬品工業株式会社 | Ｐｄ－１アゴニストからなる自己免疫疾患治療剤 |
| WO2014161509A1 (en) | 2013-04-05 | 2014-10-09 | The University Of Hong Kong | Novel pd1 isoforms, and uses thereof for potentiating immune responses |
| CA2957258C (en) * | 2014-08-05 | 2023-11-07 | MabQuest SA | Immunological reagents |
| US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| HK1254803A1 (zh) | 2015-06-23 | 2019-07-26 | Memorial Sloan Kettering Cancer Center | 新型pd -1的免疫调节剂 |
| AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
| US11034765B2 (en) | 2015-10-02 | 2021-06-15 | Symphogen A/S | Anti-PD-1 antibodies and compositions |
| CA2997799A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-pd1 antibodies and methods of use |
| EP3383412A4 (en) | 2015-12-02 | 2019-06-05 | Stcube, Inc. | SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF |
| MX2019014577A (es) | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y metodos de uso. |
-
2019
- 2019-02-18 AR ARP190100406A patent/AR114127A1/es unknown
- 2019-02-18 TW TW108105310A patent/TWI708787B/zh active
- 2019-02-22 EA EA202091809A patent/EA202091809A1/ru unknown
- 2019-02-22 AU AU2019228474A patent/AU2019228474B2/en active Active
- 2019-02-22 BR BR112020015983-2A patent/BR112020015983A2/pt unknown
- 2019-02-22 MA MA052414A patent/MA52414A/fr unknown
- 2019-02-22 CN CN202411106932.4A patent/CN118903407A/zh active Pending
- 2019-02-22 EP EP19709336.2A patent/EP3759139A1/en active Pending
- 2019-02-22 JP JP2020545727A patent/JP7071521B2/ja active Active
- 2019-02-22 CN CN201980016779.7A patent/CN111886253B/zh active Active
- 2019-02-22 PE PE2020001188A patent/PE20210045A1/es unknown
- 2019-02-22 US US16/282,609 patent/US10493148B2/en active Active
- 2019-02-22 KR KR1020207024945A patent/KR102536014B1/ko active Active
- 2019-02-22 CR CR20200375A patent/CR20200375A/es unknown
- 2019-02-22 KR KR1020237017035A patent/KR20230079458A/ko not_active Withdrawn
- 2019-02-22 WO PCT/US2019/019076 patent/WO2019168745A1/en not_active Ceased
- 2019-02-22 JO JOP/2020/0210A patent/JOP20200210A1/ar unknown
- 2019-02-22 SG SG11202008437WA patent/SG11202008437WA/en unknown
- 2019-02-22 MX MX2020009124A patent/MX2020009124A/es unknown
- 2019-02-22 CN CN202411106937.7A patent/CN118846042A/zh active Pending
- 2019-02-22 CA CA3092064A patent/CA3092064C/en active Active
- 2019-02-22 CN CN202411106929.2A patent/CN118806891A/zh active Pending
-
2020
- 2020-07-24 ZA ZA2020/04601A patent/ZA202004601B/en unknown
- 2020-07-28 IL IL276340A patent/IL276340A/en unknown
- 2020-08-05 DO DO2020000153A patent/DOP2020000153A/es unknown
- 2020-08-19 CO CONC2020/0010188A patent/CO2020010188A2/es unknown
- 2020-08-24 CL CL2020002180A patent/CL2020002180A1/es unknown
- 2020-09-01 EC ECSENADI202053544A patent/ECSP20053544A/es unknown
- 2020-09-01 PH PH12020551463A patent/PH12020551463A1/en unknown
- 2020-09-02 SA SA520420082A patent/SA520420082B1/ar unknown
-
2022
- 2022-03-07 JP JP2022034413A patent/JP7259107B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061724A patent/JP2023093549A/ja active Pending
- 2023-07-10 AU AU2023204569A patent/AU2023204569A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20221337A1 (es) | Anticuerpos trem2 y usos de estos | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| CU24636B1 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| NZ603607A (en) | Cgrp antibodies | |
| PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| NZ583605A (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20230389A1 (es) | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas | |
| PE20201494A1 (es) | Anticuerpo anti-pacap | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina |